5 Results for "

BKM-120

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "BKM-120" in MCE Product Catalog:

90
90 Cited Publications
Cat. No.: HY-70063
CAS No.: 944396-07-0
Synonyms: BKM120; NVP-BKM120
Target:  

PI3K Apoptosis

Research Areas:  

Cancer

Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with blood-brain barrier permeability. Buparlisib has IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively .
loading...
    loading...
90
90 Cited Publications
Cat. No.: HY-15180
CAS No.: 1312445-63-8
Purity:  99.88%
Synonyms: BKM120 Hydrochloride; NVP-BKM120 Hydrochloride
Buparlisib Hydrochloride (BKM120 Hydrochloride) is a CNS-penetrant pan-class I PI3K inhibitor, with IC50 of 52 nM/166 nM/116 nM/262 nM for p110α/p110β/p110δ/p110γ, respectively.
loading...
    loading...
Cat. No.: HY-70063R
CAS No.: 944396-07-0
Synonyms: BKM120 (Standard); NVP-BKM120 (Standard)
Research Areas:  

Cancer

Buparlisib (Standard) is the analytical standard of Buparlisib. This product is intended for research and analytical applications. Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.
loading...
    loading...
Cat. No.: HY-15180R
CAS No.: 1312445-63-8
Synonyms: BKM120 Hydrochloride (Standard); NVP-BKM120 Hydrochloride (Standard)
Research Areas:  

Cancer

Buparlisib (Hydrochloride) (Standard) is the analytical standard of Buparlisib (Hydrochloride). This product is intended for research and analytical applications. Buparlisib Hydrochloride (BKM120 Hydrochloride) is a pan-class I PI3K inhibitor, with IC50 of 52 nM/166 nM/116 nM/262 nM for p110α/p110β/p110δ/p110γ, respectively.
loading...
    loading...
Cat. No.: HY-184412
Target:  

SHP2 Apoptosis p38 MAPK

Research Areas:  

Cancer

SDUY104 is an orally active amide-based allosteric inhibitor of SHP2 with an IC50 of 140 nM. SDUY104 impairs KRAS-driven pancreatic cancer cell proliferation via cell-cycle arrest and apoptosis. SDUY104 suppresses MAPK signaling and triggers compensatory PI3K-AKT activation. SDUY104 can be used for KRAS-mutant pancreatic cancer research .
loading...
    loading...